Clinical Trial

The Benefits of Virtual Reality in the Care of Elderly People With Psychomotor Disadaptation Syndrome

Study acronym: VIR-AGE
Recruiting
View on ClinicalTrials.gov →
Summary
Psychomotor Disadaptation Syndrome (PMDS) is characterised by a deterioration in postural function, gait and psychomotor automatisms in the elderly. It is often associated with falls and can manifest itself as retropulsion, gait abnormalities, neurological disorders and psycho-behavioural problems. For the majority of these patients, a stay in a geriatric medical and rehabilitation centre is necessary, enabling an objective assessment of these disorders and multi-professional care, including physiotherapists, occupational therapists and adapted physical activity teachers, aimed at restoring safe movement and motor independence. However, rehabilitation relies on traditional exercises that are limited, repetitive and sometimes far removed from everyday activities. Technological innovations such as virtual reality (VR) offer opportunities to improve care by creating immersive environments that reproduce real-life situations. VR could thus help to rehabilitate the motor problems associated with MS. The aim of the VIR-AGE project is to study the clinical benefits of VR in the rehabilitation of hospitalised elderly people suffering from PMDS in terms of functional deficits, particularly motor deficits. The study will take place at the Centre gériatrique Champmaillot of the CHU Dijon Bourgogne. A total of 50 patients with SPDM will take part. The total duration of your participation is 5 weeks.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-10; most recent amendment 2026-04-20.
Status change: Not Yet Recruiting → Recruiting 2025-07-17
Trial Details
NCT Number NCT07026890
Lead Sponsor Centre Hospitalier Universitaire Dijon
Conditions Psychomotor Disadaptation Syndrome
Enrollment 50 participants
Start Date 2025-07-16
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-21